News Headlines

  1. IDT Biologika Accelerates Global Growth Through Strategic CDMO Partnership 5/20/2025

    SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that IDT Biologika, a Germany-based CDMO (Contract Development and Manufacturing Organization) and a subsidiary of SK bioscience, is accelerating its efforts to explore new business opportunities and strengthen its presence as a global CDMO through major international industry events.

  2. CellProthera Selects CELLforCURE By SEQENS For Phase 3 GMP Manufacturing 5/20/2025

    CellProthera, a regenerative cell therapy developer specializing in ischemic diseases, has chosen CELLforCURE by SEQENS, as its contract development and manufacturing organization (CDMO) partner for its planned Phase 3 trial for ProtheraCytes, its autologous expanded CD34+ stem cell-based therapy aimed at improving heart failure event-free survival following a severe heart attack.

  3. NextCell Announces Strategic Collaboration With Fujifilm Irvine Scientific 5/20/2025

    NextCell Pharma AB’s ("NextCell" or "the Company") has entered into a strategic collaboration with Fujifilm Irvine Scientific Inc. to bring together their core competences in mesenchymal stromal cells (MSCs) and raw materials for the life science sector.

  4. Bora Biologics Expands San Diego Facility For 2000L+ Scale Biologics Manufacturing, Boosting CDMO Capacity 5/20/2025

    Bora Biologics, a leading contract development and manufacturing organization (CDMO) specializing in biologics manufacturing, announced a major expansion of its U.S. FDA-registered commercial manufacturing facility in San Diego.

  5. Porton Advanced Announces Collaboration With Hualong Biological To Accelerate MATC Cell Therapy Development For Solid Tumor Treatment Breakthroughs 5/19/2025

    Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Hualong Biological, an innovator in novel cancer therapeutics.

  6. ITM And Radiopharm Sign Supply Agreement For n.c.a. Lutetium-177 5/19/2025

    ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Radiopharm Theranostics (ASX:RAD; NASDAQ: RADX “Radiopharm”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, today announced the signing of a supply agreement that will provide Radiopharm with ITM’s medical radioisotope, non-carrier-added Lutetium-177 (n.c.a. 177Lu), to enable its usage in the clinical and potential future commercial development of the 177Lu-based molecules in Radiopharm’s development pipeline.

  7. Cellino's iPSC Manufacturing Technology Receives FDA Advanced Manufacturing Technology (AMT) Designation 5/19/2025

    Cellino, a leader in advanced biomanufacturing, today announced that its optical biomanufacturing technology for generating induced pluripotent stem cells (iPSCs) has received the FDA’s Advanced Manufacturing Technology (AMT) designation from the Center for Biologics Evaluation and Research (CBER).

  8. Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress In Support Of Clinical Trial Readiness 5/15/2025

    Cadrenal Therapeutics, Inc., a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today announced manufacturing and supply chain milestones for its lead drug candidate, tecarfarin, a novel oral vitamin K antagonist (VKA) anticoagulant that is designed to address unmet needs in anticoagulation therapy.

  9. Abzena Announces Establishment Of Scientific Advisory Board To Support Innovation Strategy 5/15/2025

    Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has announced today the formation of its Scientific Advisory Board (SAB) comprised of biopharma industry experts with diversified expertise in Discovery Research & Development (R&D) and Chemistry, Manufacturing, and Controls (CMC).

  10. VintaBio Presents Data Demonstrating High-Efficiency AAV Vector Production Using Proprietary VintaProcess™ At 2025 ASGCT Annual Meeting 5/15/2025

    VintaBio, a biotech manufacturer specializing in high-yield, high-purity viral vectors for gene therapy, today presented data further demonstrating the advantages and productivity of its proprietary VintaProcess™ at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting.